Collaboration and License Agreements (Tables)

3 Months Ended

Mar. 31, 2021

Collaboration And License Agreements [Abstract]

Schedule of Revenue from Collaboration Agreements

Revenue from collaboration agreements for the three months ended March 31, 2021 and 2020 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):

	Three Months Ended March 31,
	2021		2020
Revenue from collaboration agreements:
Roche Agreement	$	2,193	$	2,269
Biogen Agreement		1,880		996
Calico Agreement		3,353		3,551
Total revenue from collaboration agreements	$	7,426	$	6,816

Schedule of Financial Information Related to Collaboration and License Agreements

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of March 31, 2021 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	750	$	9,390	$	27,396	$	36,786
Biogen Agreement		155		14,775		23,490		38,265
Calico Agreement		2,751		2,400		—		2,400
Total	$	3,656	$	26,565	$	50,886	$	77,451

Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2020 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	750	$	11,238	$	26,991	$	38,229
Biogen Agreement		776		13,965		26,026		39,991
Calico Agreement		2,958		2,400		600		3,000
Total	$	4,484	$	27,603	$	53,617	$	81,220

Schedule of Supplemental Financial Information Related to Collaboration and License Agreements

Supplemental financial information related to the collaboration and license agreements for the three months ended March 31, 2021 and 2020 are (in thousands):

	Three Months Ended March 31,
	2021		2020
Revenue recognized that was included in the contract liability at the beginning of the period	$	4,519	$	3,496
Revenue recognized from performance obligations fully or partially satisfied in previous periods		—		—
Aggregate amount of the transaction price allocated to the performance obligations that are partially or fully unsatisfied as of the end of the reporting period		86,618		100,427